Is cosentyx suitable for long term treatment?

How long can patients stay on Cosentyx?

Clinical studies show that many people continue Cosentyx for two years or longer while maintaining control of their psoriasis, psoriatic arthritis, or ankylosing spondylitis. Open-label extension trials tracked participants through five years with no new safety signals emerging beyond the known risks.

Does effectiveness hold up over time?

Response rates generally remain stable after the first year. In the psoriasis program, PASI-75 scores stayed above 80 percent at week 260 for those who stayed on therapy. Similar durability appears in the arthritis and spondyloarthritis trials.

What side effects matter most for long-term use?

The main ongoing concern is infection risk, particularly upper-respiratory and candida infections. Tuberculosis screening and periodic lab monitoring are recommended. Rates of serious adverse events did not increase markedly between year one and year five in the extension studies.

When should treatment be stopped or switched?

Doctors usually continue Cosentyx as long as it controls symptoms and side effects stay manageable. Loss of response, recurrent infections, or new contraindications (such as inflammatory bowel disease flare) can prompt a switch to another biologic.

Can biosimilars affect long-term access?

The main Cosentyx patents begin to expire in the United States around 2029, with some formulation patents extending into the early 2030s. Biosimilar competition after that point could lower cost and expand access for patients who need chronic therapy.